Rodger Euan J, Gimenez Gregory, Ajithkumar Priyadarshana, Stockwell Peter A, Almomani Suzan, Bowden Sarah A, Leichter Anna L, Ahn Antonio, Pattison Sharon, McCall John L, Schmeier Sebastian, Frizelle Frank A, Eccles Michael R, Purcell Rachel V, Chatterjee Aniruddha
Department of Pathology, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
iScience. 2023 May 28;26(6):106986. doi: 10.1016/j.isci.2023.106986. eCollection 2023 Jun 16.
Colorectal cancer (CRC) is a leading cause of morbidity and mortality worldwide. The majority of CRC deaths are caused by tumor metastasis, even following treatment. There is strong evidence for epigenetic changes, such as DNA methylation, accompanying CRC metastasis and poorer patient survival. Earlier detection and a better understanding of molecular drivers for CRC metastasis are of critical clinical importance. Here, we identify a signature of advanced CRC metastasis by performing whole genome-scale DNA methylation and full transcriptome analyses of paired primary cancers and liver metastases from CRC patients. We observed striking methylation differences between primary and metastatic pairs. A subset of loci showed coordinated methylation-expression changes, suggesting these are potentially epigenetic drivers that control the expression of critical genes in the metastatic cascade. The identification of CRC epigenomic markers of metastasis has the potential to enable better outcome prediction and lead to the discovery of new therapeutic targets.
结直肠癌(CRC)是全球发病和死亡的主要原因之一。即使经过治疗,大多数CRC死亡也是由肿瘤转移引起的。有强有力的证据表明,诸如DNA甲基化等表观遗传变化与CRC转移及患者较差的生存率相关。早期检测以及更好地了解CRC转移的分子驱动因素具有至关重要的临床意义。在此,我们通过对CRC患者的配对原发性癌症和肝转移灶进行全基因组规模的DNA甲基化和全转录组分析,确定了晚期CRC转移的一个特征。我们观察到原发性和转移灶配对之间存在显著的甲基化差异。一部分位点显示出甲基化 - 表达的协同变化,这表明这些可能是控制转移级联反应中关键基因表达的潜在表观遗传驱动因素。CRC转移表观基因组标志物的鉴定有可能实现更好的预后预测,并导致发现新的治疗靶点。
iScience. 2023-5-28
Mol Biol Rep. 2023-7
Clin Cancer Res. 2011-1-28
Nat Rev Gastroenterol Hepatol. 2011-10-18
Clin Epigenetics. 2020-11-30
Bladder Cancer. 2025-8-21
Oncol Rep. 2025-10
Lab Chip. 2025-7-21
Cancer Biol Med. 2025-6-26
Methods Mol Biol. 2025
ACS Pharmacol Transl Sci. 2025-4-10
Cancers (Basel). 2024-2-23
Comput Struct Biotechnol J. 2024-2-3
Methods Mol Biol. 2023
Signal Transduct Target Ther. 2022-3-4
Methods Mol Biol. 2022
Methods Mol Biol. 2022
Cancer Discov. 2022-1
Trends Cancer. 2022-3
Biochem J. 2021-9-17